Humacyte (@humacyte) / X

Humacyte

584 posts

Humacyte

@humacyte

The Turning Point in Regenerative Medicine.

Research Triangle Park, N.C.

Joined December 2020

Pinned
Humacyte
@humacyte
Dec 23, 2024
Humacyte is proud to announce that the FDA has granted full approval for Symvess™, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. This approval is a significant milestone in regenerative medicine,
00:00
27K
Humacyte
@humacyte
Dec 20, 2024
Humacyte is proud to announce that the FDA has granted full approval for our Acellular Tissue Engineered Vessel, a first-in-class, universally implantable, bioengineered human vessel for extremity arterial trauma. This approval is a significant milestone in regenerative medicine,
14K
Humacyte
@humacyte
Feb 26, 2025
Humacyte is proud to announce the full commercial launch of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma. ✅ FDA Approved: Full Biologics License Application (BLA) approval granted on Dec 19, 2024. ✅ Commercial Shipments: FDA has authorized
7K
Humacyte
@humacyte
Mar 27, 2025
Dr. Laura Niklason, M.D., Ph.D., President and CEO of Humacyte, Inc., responds to this week's New York Times article. ➡️ Read her statement at the end of the document here: humacyte.gcs-web.com/static-files/9… #Humacyte $HUMA
8.6K
Humacyte
@humacyte
Apr 4, 2025
🏅 Humacyte is thrilled to announce the first units sold of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma. This marks a pivotal step forward in our mission to enhance patient care. In addition, since our commercial launch a few short weeks
4.4K
Humacyte
@humacyte
Feb 13, 2025
The Humacyte sales team had an excellent final training week in January, gearing up for commercial launch. This follows the recent Biologics License Application approval of Symvess™ Acellular Tissue Engineered Vessel-tyod in late December 2024. The excitement for the full
00:00
14K
Humacyte
@humacyte
Jul 24, 2025
Major Milestone in Biotech Options for the U.S. Military Humacyte has officially made its first sale of Symvess™, a bioengineered human vessel, to a U.S. Military Treatment Facility—marking a breakthrough in patient care for service members and veterans. Following FDA approval
3.2K
Humacyte
@humacyte
Jul 9, 2025
Humacyte has just announced that Symvess™ has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency, which makes Symvess available to healthcare professionals at U.S. Department of Defense and U.S. Department of Veterans Affairs
5.3K
Humacyte
@humacyte
Nov 14, 2025
We are excited to share that Symvess™ acellular tissue engineered vessel-tyod (ATEV™), has been selected as @biotech breakthrough ’s MedTech Innovation of the Year! The Biotech Breakthrough Awards recognize the companies, products, and services breaking new ground in life
9.3K
Humacyte
@humacyte
Jun 9, 2025
Mohamad A. Hussain, MD, PhD, Vascular and Endovascular Surgeon at Brigham and Women’s Hospital and Assistant Professor of Surgery Harvard Medical School and lead author of the V007 AV access hemodialysis study of Humacyte’s Acellular Tissue Engineered Vessel (ATEV™) presented
2.7K
Humacyte
@humacyte
Mar 11, 2025
Humacyte is proud to announce the publication of our Budget Impact Model (BIM) for the Acellular Tissue Engineered Vessel (ATEV™) in the Journal of Medical Economics. For more details, please read the full press release here: investors.humacyte.com/news-releases/… #Humacyte
3K
Humacyte
@humacyte
May 14, 2025
Humacyte has just released first quarter 2025 financial results and provided a business update, highlighting progress made in the U.S. commercial launch and pipeline projects, as well as other corporate initiatives. Key updates include: · The first commercial shipments were made
3.5K
Humacyte
@humacyte
Jan 31, 2025
In a recent interview and article published on @WIRED , Humacyte’s recent FDA approval was highlighted as a true milestone moment in bioengineering and healthcare. Through the interview, Laura Niklason, PhD, MD, Founder and CEO of Humacyte, shared details about our revolutionary
4.2K
Humacyte
@humacyte
Feb 9, 2024
Just In: The FDA has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel™ (HAV™) for the treatment of vascular trauma.
investors.humacyte.com
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA...
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine – – The HAV...
10K